Long noncoding RNAs (lncRNAs) are increasingly recognized for their role in cancer progression. The previously uncharacterized lncRNA MAYA is now shown to promote bone metastasis by bridging ROR1–HER3 and Hippo–YAP pathways. Neuregulin-induced HER3 phosphorylation by ROR1 recruits a MAYA-containing protein complex to methylate Hippo/MST1 and activate YAP target genes that are essential for bone metastasis.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
FOXC1-mediated LINC00301 facilitates tumor progression and triggers an immune-suppressing microenvironment in non-small cell lung cancer by regulating the HIF1α pathway
Genome Medicine Open Access 02 September 2020
-
The lncRNA MIR2052HG regulates ERα levels and aromatase inhibitor resistance through LMTK3 by recruiting EGR1
Breast Cancer Research Open Access 03 April 2019
-
Development of Effective Therapeutics Targeting HER3 for Cancer Treatment
Biological Procedures Online Open Access 19 March 2019
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Weilbaecher, K. N., Guise, T. A. & McCauley, L. K. Nat. Rev. Cancer 11, 411–425 (2011).
Moroishi, T., Hansen, C. G. & Guan, K. L. Nat. Rev. Cancer 15, 73–79 (2015).
Chen, D. et al. Nat. Med. 18, 1511–1517 (2012).
Shimo, T. et al. J. Bone Miner. Res. 21, 1045–1059 (2006).
Attisano, L. & Wrana, J. L. F1000Prime Rep. 5, 17 (2013).
Fan, R., Kim, N.-G. & Gumbiner, B. M. Proc. Natl Acad. Sci. USA 110, 2569–2574 (2013).
Arteaga, C. L. & Engelman, J. A. Cancer Cell 25, 282–303 (2014).
Sergina, N. V. et al. Nature 445, 437–441 (2007).
Li, C. et al. Nat. Cell Biol. 19, 106–119 (2017).
Borcherding, N., Kusner, D., Liu, G.-H. & Zhang, W. Protein Cell 5, 496–502 (2014).
Johnson, R. & Halder, G. Nat. Rev. Drug Discov. 13, 63–79 (2014).
Geisler, S. & Coller, J. Nat. Rev. Mol. Cell Biol. 14, 699–712 (2013).
Wang, P. et al. Science 344, 310–313 (2014).
Liu, B. et al. Cancer Cell 27, 370–381 (2015).
Denkert, C., Liedtke, C., Tutt, A. & von Minckwitz, G. Lancet http://doi.org/bww5 (2016).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Zhuo, W., Kang, Y. Lnc-ing ROR1–HER3 and Hippo signalling in metastasis. Nat Cell Biol 19, 81–83 (2017). https://doi.org/10.1038/ncb3467
Published:
Issue Date:
DOI: https://doi.org/10.1038/ncb3467
This article is cited by
-
SIBP-03, a novel anti-HER3 antibody, exerts antitumor effects and synergizes with EGFR- and HER2-targeted drugs
Acta Pharmacologica Sinica (2024)
-
Understanding crosstalk of organ tropism, tumor microenvironment and noncoding RNAs in breast cancer metastasis
Molecular Biology Reports (2023)
-
FOXC1-mediated LINC00301 facilitates tumor progression and triggers an immune-suppressing microenvironment in non-small cell lung cancer by regulating the HIF1α pathway
Genome Medicine (2020)
-
The lncRNA MIR2052HG regulates ERα levels and aromatase inhibitor resistance through LMTK3 by recruiting EGR1
Breast Cancer Research (2019)
-
Development of Effective Therapeutics Targeting HER3 for Cancer Treatment
Biological Procedures Online (2019)
